Function-oriented synthesis, step economy, and drug design

被引:977
作者
Wender, Paul A. [1 ]
Verma, Vishal A. [1 ]
Paxton, Thomas J. [1 ]
Pillow, Thomas H. [1 ]
机构
[1] Stanford Univ, Dept Chem, Stanford, CA 94305 USA
关键词
D O I
10.1021/ar700155p
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
This Account provides an overview and examples of function-oriented synthesis (FOS) and its increasingly important role in producing therapeutic leads that can be made in a step-economical fashion. Biologically active natural product leads often suffer from several deficiencies. Many are scarce or difficult to obtain from natural sources. Often, they are highly complex molecules and thus not amenable to a practical synthesis that would impact supply. Most are not optimally suitable for human therapeutic use. The central principle of FOS is that the function of a biologically active lead structure can be recapitulated, tuned, or greatly enhanced with simpler scaffolds designed for ease of synthesis and also synthetic innovation. This approach can provide practical access to new (designed) structures with novel activities while at the same time allowing for synthetic innovation by target design. This FOS approach has been applied to a number of therapeutically important natural product leads, For example, bryostatin is a unique natural product anticancer lead that restores apoptosis in cancer cells, reverses multidrug resistance, and bolsters the immune system. Remarkably, it also improves cognition and memory in animals. We have designed and synthesized simplified analogs of bryostatin that can be made in a practical fashion (pilot scale) and are superior to bryostatin in numerous assays including growth inhibition in a variety of human cancer cell lines and in animal models. Laulimalide is another exciting anticancer lead that stabilizes microtubules, like paclitaxel, but unlike paclitaxel, it is effective against multidrug-resistant cell lines. Laulimalide suffers from availability and stability problems, issues that have been addressed using FOS through the design and synthesis of stable and efficacious laulimalide analogs. Another FOS program has been directed at the design and synthesis of drug delivery systems for enabling or enhancing the uptake of drugs or drug candidates into cells and tissue. We have generated improved transporters that can deliver agents in a superior fashion compared with naturally occurring cell-penetrating peptides and that can be synthesized in a practical and step-economical fashion. The use of FOS has allowed for the translation of exciting, biologically active natural product leads into simplified analogs with superior function. This approach enables the development of synthetically innovative strategies while targeting therapeutically novel structures.
引用
收藏
页码:40 / 49
页数:10
相关论文
共 64 条
  • [31] Knowledge of the proposed chemical mechanism of action and cytochrome P450 metabolism of antimalarial trioxanes like artemisinin allows rational design of new antimalarial peroxides
    Posner, GH
    O'Neill, PM
    [J]. ACCOUNTS OF CHEMICAL RESEARCH, 2004, 37 (06) : 397 - 404
  • [32] The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity
    Pryor, DE
    O'Brate, A
    Bilcer, G
    Díaz, JF
    Wang, YF
    Wang, Y
    Kabaki, M
    Jung, MK
    Andreu, JM
    Ghosh, AK
    Giannakakou, P
    Hamel, E
    [J]. BIOCHEMISTRY, 2002, 41 (29) : 9109 - 9115
  • [33] FIJIANOLIDES, POLYKETIDE HETEROCYCLES FROM A MARINE SPONGE
    QUINOA, E
    KAKOU, Y
    CREWS, P
    [J]. JOURNAL OF ORGANIC CHEMISTRY, 1988, 53 (15) : 3642 - 3644
  • [34] Roth BD, 2002, PROGR MED CHEM, V40, P1, DOI 10.1016/S0079-6468(08)70080-8
  • [35] THE LARGE-SCALE ISOLATION OF BRYOSTATIN-1 FROM BUGULA-NERITINA FOLLOWING CURRENT GOOD MANUFACTURING PRACTICES
    SCHAUFELBERGER, DE
    KOLECK, MP
    BEUTLER, JA
    VATAKIS, AM
    ALVARADO, AB
    ANDREWS, P
    MARZO, LV
    MUSCHIK, GM
    ROACH, J
    ROSS, JT
    LEBHERZ, WB
    REEVES, MP
    EBERWEIN, RM
    RODGERS, LL
    TESTERMAN, RP
    SNADER, KM
    FORENZA, S
    [J]. JOURNAL OF NATURAL PRODUCTS, 1991, 54 (05): : 1265 - 1270
  • [36] The total synthesis of dynemicin A leading to development of a fully contained bioreductively activated enediyne prodrug
    Shair, MD
    Yoon, TY
    Mosny, KK
    Chou, TC
    Danishefsky, SJ
    [J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1996, 118 (40) : 9509 - 9525
  • [37] Design and synthesis of a potent phorboxazole C(11-15) acetal analogue
    Smith, AB
    Razler, TM
    Meis, RM
    Pettit, GR
    [J]. ORGANIC LETTERS, 2006, 8 (04) : 797 - 799
  • [38] Reduction of Escherichia coli O157:H7 and Salmonella in ground beef using lactic acid bacteria and the impact on sensory properties
    Smith, L
    Mann, JE
    Harris, K
    Miller, MF
    Brashears, MM
    [J]. JOURNAL OF FOOD PROTECTION, 2005, 68 (08) : 1587 - 1592
  • [39] Identification of the putative bryostatin polyketide synthase gene cluster from "Candidatus endobugula sertula", the uncultivated microbial symbiont of the marine bryozoan Bugula neritina
    Sudek, Sebastian
    Lopanik, Nicole B.
    Waggoner, Laura E.
    Hildebrand, Mark
    Anderson, Christine
    Liu, Haibin
    Patel, Amrish
    Sherman, David H.
    Haygood, Margo G.
    [J]. JOURNAL OF NATURAL PRODUCTS, 2007, 70 (01): : 67 - 74
  • [40] Protein kinase inhibition: natural and synthetic variations on a theme
    Taylor, SS
    Radzio-Andzelm, E
    [J]. CURRENT OPINION IN CHEMICAL BIOLOGY, 1997, 1 (02) : 219 - 226